Pancreatic Cancer Research

ResearcherErasmus MCActive in the last 2 years

Ferry A.L.M. Eskens

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0009-0000-3870-5100; OpenAlex author ID A5112538610. Sources: ClinicalTrials.gov.

Their work

Papers
9
Trials
1 (principal investigator on 1)
Grants
0
Labs led
0
Collaborators
36
Papers, trials and grants by year

2018: 1 paper · 2019: 1 paper · 2020: 3 papers · 2021: 1 paper, 1 trial · 2022: 1 paper · 2023: none · 2024: none · 2025: 2 papers

Papers 9

  1. REACtiVe-2: phase I evaluation of dendritic cell vaccination and agonistic CD40 therapy following (m)FOLFIRINOX in metastatic pancreatic cancer. Co-author DOI 10.1038/s41467-025-66092-1↗
  2. Delayed gastric emptying after pancreatic cancer surgery impacts time to start of adjuvant treatment but not overall survival: a post-hoc analysis of the PREOP… Co-author DOI 10.1093/bjs/znaf261↗
  3. Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREO… Co-author DOI 10.1200/jco.21.02233↗
  4. A phase II study of stereotactic radiotherapy after FOLFIRINOX for locally advanced pancreatic cancer (LAPC-1 trial): Long-term outcome. Co-author DOI 10.1016/j.radonc.2020.11.006↗
  5. The yield of chest computed tomography in patients with locally advanced pancreatic cancer. Co-author DOI 10.1002/jso.25968↗
  6. Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung… Co-author DOI 10.1038/s41416-020-0776-z↗
  7. Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III P… Co-author DOI 10.1200/jco.19.02274↗
  8. Efficacy and feasibility of stereotactic radiotherapy after folfirinox in patients with locally advanced pancreatic cancer (LAPC-1 trial). Co-author DOI 10.1016/j.eclinm.2019.10.013↗
  9. FOLFIRINOX and radiotherapy for locally advanced pancreatic cancer: A cohort study. Co-author DOI 10.1002/jso.25233↗

Trials 1

  1. MesoPher/Mitazalimab-combination Therapy in Metastatic Pancreatic Disease (REACtiVe-2 Trial) Principal investigator NCT05650918↗

Closest collaborators

The 25 strongest of 36 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Casper H.J. van Eijck · 7 shared papers, 2018–2025 · strength 0.84
  2. Mustafa Suker · 6 shared papers, 2018–2022 · strength 0.65
  3. Joost J.M.E. Nuyttens · 6 shared papers, 2018–2022 · strength 0.65
  4. Bas Groot Koerkamp · 5 shared papers, 2018–2022 · strength 0.49
  5. Marjolein Y.V. Homs · 4 shared papers, 2020–2025 · strength 0.49
  6. Judith de Vos‐Geelen · 3 shared papers, 2020–2025 · strength 0.36
  7. Bert A. Bonsing · 3 shared papers, 2019–2022 · strength 0.26
  8. Casper W.F. van Eijck · 1 shared paper, 2025 · strength 0.18
  9. Michail Doukas · 1 shared paper, 2025 · strength 0.18
  10. Marcella Willemsen · 1 shared paper, 2025 · strength 0.18
  11. Aniek E. van Diepen · 1 shared paper, 2025 · strength 0.18
  12. Freek R. van ‘t Land · 1 shared paper, 2025 · strength 0.18
  13. Songul Kucukcelebi · 1 shared paper, 2025 · strength 0.18
  14. Gijs A. Patijn · 2 shared papers, 2020–2022 · strength 0.18
  15. Johanna W. Wilmink · 2 shared papers, 2020–2022 · strength 0.18
  16. Geertjan van Tienhoven · 2 shared papers, 2020–2022 · strength 0.18
  17. Jeanin Elise van Hooft · 2 shared papers, 2020–2022 · strength 0.18
  18. Geert‐Jan Creemers · 2 shared papers, 2020–2022 · strength 0.18
  19. Sebastiaan Festen · 2 shared papers, 2020–2022 · strength 0.18
  20. Ignace H. J. T. de Hingh · 2 shared papers, 2020–2022 · strength 0.18
  21. Eva Versteijne · 2 shared papers, 2020–2022 · strength 0.18
  22. Marc G. Besselink · 2 shared papers, 2020–2022 · strength 0.18
  23. Mauro Loi · 1 shared paper, 2021 · strength 0.16
  24. Maria Ausilia Teriaca · 1 shared paper, 2021 · strength 0.16
  25. Jacob L. van Dam · 1 shared paper, 2022 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.